Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer

Gynecologic Oncology

Volumn 133, Issue 1, 2014, Pages 11-15

  Slaughter, Katrina N ^a   Thai, Theresa ^a   Penaroza, Shayla ^a   Benbrook, Doris M ^a   Thavathiru, Elangovan ^a   Ding, Kai ^a   Nelson, Tina ^a   McMeekin, D Scott ^a   Moore, Kathleen N ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Angiogenesis; Clinical biomarker; Subcutaneous fat; Visceral fat

Indexed keywords

ANGIOPOIETIN 2; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; VASCULOTROPIN;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; INTRAABDOMINAL FAT; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBESITY; OVARY CARCINOMA; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOLOGIST; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; SUBCUTANEOUS FAT;

ANGIOGENESIS; CLINICAL BIOMARKER; SUBCUTANEOUS FAT; VISCERAL FAT;

ADIPOSITY; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CARBOPLATIN; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OBESITY; OVARIAN NEOPLASMS; OVERWEIGHT; PACLITAXEL; PILOT PROJECTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SUBCUTANEOUS FAT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897099003     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.01.031     Document Type: Article

References (19)

1. R.A. Burger, M.F. Brady, and M.A. Bookman et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study J Clin Oncol 28 18 2010 [(suppl):LBA1]
2. T. Perren, A.M. Swart, and J. Pfisterer et al. ICON7: a phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) Ann Oncol 21 2010 [viii2Yviii3]
3. A.G. Reneham, M. Tyson, M. Egger, R.F. Heller, and M. Zwahlen Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 381 2008 569 578
4. J.V. Silha, M. Krsek, and P. Sucharda et al. Angiogenic factors are elevated in overweight and obese individuals Int J Obes (Lond) 29 2005 1308 1314
5. S. Miyazawe-Hoshimoto, K. Takahashi, and H. Bujo et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects Diabetologia 46 2003 1483 1488
6. K. Tokunaga, Y. Matsuzawa, and K. Ishikawa et al. A novel technique for the determination of body fat by computed tomography Int J Obes 7 1983 437 445
7. T. Yoshizumi, T. Makamura, and M. Yamane et al. Abdominal fat: standardized technique for measurement at CT Radiology 211 1999 283 286
8. S.C. Modesitt, J.Y. Hsu, and S.R. Chowbina et al. Not all fat is equal differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer Int J Gynecol Cancer 22 5 2012 732 741
9. E. Dusserre, P. Moulin, and H. Vidal Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues Biochem Biophys Acta 1500 2000 88 96
10. B. Guiu, J.M. Petit, and F. Bonnetain et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer Gut 59 2010 341 347
11. L. Simkens, M. Koopman, and L. Mol et al. Influence of body mass index on outcomes in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy Eur J Cancer 47 2011 2560 2567
12. S. Ladoire, F. Bonnetain, and M. Gauthier et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents Oncologist 16 2011 71 81
13. T.K. Choueiri, W. Xie, and C.K. Kollmannsberger et al. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration [abstract 4524] Presented at the 2010 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 4-8 2010
14. S. Steffens, V. Grunwald, and K. Ringe et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist 16 2011 1565 1571
15. M.S. Tsao, A. Sakurada, and J.C. Cutz et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
16. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 8 2008 592 603
17. Y. Sato The vasohibin family: a novel family for angiogenesis regulation J Biochem 153 1 2013 5 11
18. Y. Cao Angiogenesis modulates adipogenesis and obesity J Clin Invest 117 2007 2362 2368
19. R.N. Eskander, and K.S. Tewari Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma - mechanistics, review of phase III randomized clinical trials, and regulatory implications Gynecol Oncol 132 2 2013 496 505